 |
市场调查报告书
商品编码
1608747
特种注射剂市场：依药物类型、应用、通路、地区Specialty Injectable Market, By Drug Type, By Application, By Distribution Channel, By Geography |
||||||
特种注射剂市场预计到2024年将达到569.2亿美元，预计到2031年将达到1,094.5亿美元，2024年至2031年的复合年增长率为9.8%。
| 分析范围 | 分析详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 市场规模（2024年） | 569.2亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测期复合年增长率（2024-2031） | 9.80% | 预计金额（2031年） | 1094.5亿美元 |
特种注射剂是指皮下、静脉注射、肌肉或玻璃体内给药的注射药物疗法。这些注射剂用于多种治疗领域，包括癌症、风湿病、心血管、自体免疫和中枢神经系统。近年来，生技药品和标靶治疗的进步以及世界老年人口的不断增长正在推动对特种注射剂的需求。此外，复杂的药物传递机制和功效增强的下一代药物/器械组合产品的出现也导致了采用率的提高。一些製药公司正在大力投资专业药物发现和生物相似药市场开拓，以满足新兴市场不断增长的需求。
市场动态
全球特种注射剂市场的成长是由慢性病患病率上升、更容易患各种疾病的老年人口增加、医疗保健成本上升和技术进步所推动的。此外，创新生技药品的出现和基因疗法的采用正在创造利润丰厚的机会。然而，特殊药物的高开发成本、严格的监管途径和复杂的冷供应链管理带来了重大挑战。市场面临重磅药物专利到期的威胁。製药公司正致力于透过研究合作和收购来扩大产品平臺，这可能会在预测期内推动市场成长。
本报告的主要特点
本报告对全球特种注射剂市场进行了详细分析，以 2023 年为基准年估计了预测期内（2024-2031 年）的市场规模（十亿美元）和復合年增长率（CAGR，%）。
它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
基于公司亮点、产品系列、主要亮点、绩效和策略等参数的全球特种注射剂市场的主要企业概况。
本报告涵盖的主要企业包括辉瑞、礼来公司、梯瓦製药工业公司、诺华公司、Lupin、Mylan NV、Par Pharmaceuticals、Hikma Pharmaceutical PLC、Sargent・Inincludes Pharmaceuticals、Biogen、Dr. Reddy's Laboratories Ltd.、Amgen、Astra Zeneca、太阳製药工业有限公司
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球特种注射剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球特种注射剂市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 分析目的与前提
- 分析目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 企业合併(M&A) 场景
- 市场趋势
第 4 章 特种注射剂市场：依药物类型划分，2019-2031 年（十亿美元）
- 小分子药物
- 生技药品
第五章 特种注射剂市场：按应用划分，2019-2031 年（十亿美元）
- 瘤
- 心血管疾病
- 感染疾病
- 自体免疫疾病
- 其他的
第六章 特种注射剂市场：依通路划分，2019-2031 年（十亿美元）
- 医院药房
- 零售药房
- 网路药房
第 7 章 特种注射剂市场：按地区划分，2019-2031 年（十亿美元）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- Pfizer, Inc.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lupin
- Mylan NV
- Par Pharmaceutical
- Hikma Pharmaceutical PLC
- Sagent Pharmaceuticals, Inc.
- Biogen
- Reddy's Laboratories Ltd.
- Amgen Inc.
- AstraZeneca
- Sun Pharmaceutical Industries Ltd.
第九章 分析师建议
- 《命运之轮》
- 分析师观点
- Coherent Opportunity Map (COM)
第10章 参考文献与调查方法
- 参考
- 分析方法
- 关于相干市场洞察
Specialty injectable market is estimated to be valued at USD 56.92 Bn in 2024 and is expected to reach USD 109.45 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 56.92 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 9.80% | 2031 Value Projection: | 109.45 Bn |
Specialty injectable refers to injectable drug therapies that are administered through sites such as subcutaneous, intravenous, intramuscular, and intravitreal routes. These injectables are used across several therapeutic areas including oncology, rheumatology, cardiovascular, autoimmune, and central nervous system indications. Advancements in biologics and targeted therapies along with growing geriatric population globally have boosted demand for specialty injectables in recent years. Moreover, advent of complex drug delivery mechanisms and next-generation drug-device combination products with enhanced efficacy have led to its increased adoption rate. Several pharmaceutical companies are investing heavily in specialized drug discovery and development of biosimilars to cater to growing needs in the market.
Market Dynamics
Global specialty injectable market growth is driven by rising incidence of chronic diseases, growing geriatric population prone to various illnesses, increase in healthcare spending, and technological progressions. Furthermore, emergence of innovative biologics and adoption of gene therapy has created lucrative opportunities. However, high development costs of specialty drugs, stringent regulatory pathways, and complex Cold supply chain management pose significant challenges. The market faces threats from patent expiries of blockbuster drugs. Pharmaceutical players are focusing on widening their product pipelines through research collaborations as well as acquisitions, and this can drive the market growth over the forecast period.
Key features of the study
This report provides in-depth analysis of the global specialty injectable market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global specialty injectable market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Lupin, Mylan N.V., Par Pharmaceutical, Hikma Pharmaceutical PLC, Sagent Pharmaceuticals, Inc., Biogen, Dr. Reddy's Laboratories Ltd., Amgen Inc., AstraZeneca, Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global specialty injectable market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global specialty injectable market
Market Segmentation
- By Drug Type Insights (Revenue, USD, 2019 - 2031)
- Small Molecule Drugs
- Biologics
- By Application Insights (Revenue, USD, 2019 - 2031)
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Autoimmune Disorders
- Others
- By Distribution Channel Insights (Revenue, USD, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer, Inc.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lupin
- Mylan N.V.
- Par Pharmaceutical
- Hikma Pharmaceutical PLC
- Sagent Pharmaceuticals, Inc.
- Biogen
- Reddy's Laboratories Ltd.
- Amgen Inc.
- AstraZeneca
- Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Specialty Injectable Market, By Drug Type
- Specialty Injectable Market, By Application
- Specialty Injectable Market, By Distribution Channel
- Specialty Injectable Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Market Trends
4. Specialty Injectable Market, By Drug Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Small Molecule Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Specialty Injectable Market, By Application, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Specialty Injectable Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Specialty Injectable Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Par Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceutical PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sagent Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
肌苷注射液市场，按产品类型、应用、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测
到 2030 年克林霉素磷酸酯注射液市场预测：按类型、配方、给药方法、分销管道、应用、最终用户和地区进行的全球分析
无菌注射剂市场：按分子类型、药物、适应症、分布划分 - 全球预测 2025-2030
注射市场：按分子类型、药物类别、注射途径和应用划分 - 2025-2030 年全球预测
缓释性注射剂市场：按剂量、给药途径和最终用户 - 2025-2030 年全球预测
肌内药物稀释剂市场：按产品和应用分类 - 全球预测 2025-2030
无菌注射契约製造的市场规模、份额和趋势分析报告：按分子类型、给药途径、治疗用途、最终用途、地区和细分市场进行预测，2025-2030
克林霉素磷酸酯注射液市场，规模，占有率，趋势，产业分析报告:各类型，各终端用户，各地区 - 市场预测，2024年～2032年
无菌注射药物市场，按药物类型、给药途径、药物类别、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测
肌内药物稀释剂市场，按药物类型、类型、形式、应用、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测